Clinical Trial

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2025-02-18; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-03-05
Trial Details
NCT Number NCT06842355
Lead Sponsor Tyra Biosciences, Inc
Conditions Achondroplasia
Enrollment 92 participants
Start Date 2025-03-04
Primary Completion 2030-01 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-31